Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 8:16:1721-1729.
doi: 10.2147/DMSO.S407511. eCollection 2023.

Comparison of Pathway Referrals for Liver Fibrosis Risk Stratification Performed in Diabetology and Nutrition Clinics

Cyrielle Caussy  1   2   3 , Charlène Telliam  2   4 , Bader Al-Nuaimi  2 , Marianne Maynard-Muet  5   6 , Jérôme Dumortier  3   7 , Fabien Zoulim  3   5   6 , Emmanuel Disse  1   2   3 , Cyrille Colin  3   8 , Massimo Levrero  3   5   6 , Philippe Moulin  1   3   4
Affiliations

Comparison of Pathway Referrals for Liver Fibrosis Risk Stratification Performed in Diabetology and Nutrition Clinics

Cyrielle Caussy et al. Diabetes Metab Syndr Obes. .

Abstract

Purpose: A systematic screening for the presence of nonalcoholic fatty liver disease (NAFLD)-related advanced fibrosis is currently recommended in patients with type 2 diabetes mellitus (T2DM) and obesity. However, real-world data of such liver fibrosis risk stratification pathway from diabetology and nutrition clinics towards hepatology clinics are scarce. Therefore, we compared data from two pathways with or without transient elastography (TE) performed in diabetology and nutrition clinics.

Patients and methods: This is a retrospective study comparing the proportion of patients with intermediate/high risk of advanced fibrosis (AF) as defined by a liver stiffness measurement (LSM) ≥8kPa, among patients referred in hepatology from two diabetology-nutrition departments at Lyon University Hospital, France between November 1st 2018 to December 31st 2019.

Results: Among the two diabetology and nutrition departments using TE or not, 27.5% (62/225) versus 44.2% (126/285) were referred to hepatology, respectively. The pathway using TE in diabetology and nutrition referred to hepatology a higher proportion of patients with intermediate/high risk of AF compared to the pathway without TE: 77.4% versus 30.9%, p<0.001. In the pathway with TE, the odds of patients with intermediate/high risk of AF referred to hepatology was significantly higher: OR: 7.7, 95% CI: 3.6-16.7, p<0.001 after adjustment for age, sex and presence of obesity and T2D compared to the pathway without TE in diabetology and nutrition clinics. However, among the patients not referred, 29.4% had an intermediate/high risk of AF.

Conclusion: A pathway-referral using TE performed in diabetology and nutrition clinics, significantly improves the liver fibrosis risk stratification and avoids over-referral. However, collaboration between diabetologist, nutritionists and hepatologists is needed to avoid under-referral.

Keywords: FibroScan; cirrhosis; nonalcoholic fatty liver disease; obesity; screening; transient elastography; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Pr Cyrielle Caussy received consultant fees from Gilead, NovoNordisk, AstraZeneca, Lilly, Bayer, E-scopics, Intercept, MSD, Bayer and Echosens. She received grant support from Gilead and E-scopics. Pr Philippe Moulin received honoraria from AKCEA AMGEN AMRYT IONIS NovoNordisk paid to him and/or his institutions. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Comparison of pathway referrals for risk stratification of liver fibrosis with and without TE in diabetology and nutrition clinics.
See this image and copyright information in PMC

References

    1. Younossi ZM, Henry L. Fatty liver through the ages: nonalcoholic steatohepatitis. Endocr Pract. 2022;28(2):204–213. doi:10.1016/j.eprac.2021.12.010 - DOI - PubMed
    1. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–54 e1–e9; quiz e39–e40. doi:10.1016/j.cgh.2014.04.014 - DOI - PMC - PubMed
    1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–285. doi:10.1111/j.1365-2036.2011.04724.x - DOI - PubMed
    1. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003;98(9):2042–2047. doi:10.1111/j.1572-0241.2003.07659.x - DOI - PubMed
    1. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–97 e10. doi:10.1053/j.gastro.2015.04.043 - DOI - PMC - PubMed

LinkOut - more resources